# A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)

Source: https://onco.cc/trials/nct07501559/  
OnCo record `nct07501559` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JL15003Injection in glioma & glioblastoma, run by Jecho Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) is a phase 1/2 interventional study registered as NCT07501559 by Jecho Biopharmaceuticals Co., Ltd., with 40 participants planned, started 2026-06-17 and due to reach its primary completion in 2030-04. Interventions recorded: JL15003Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07501559
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
- Sponsor: Jecho Biopharmaceuticals Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07501559: https://clinicaltrials.gov/study/NCT07501559

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07501559.json